C-Peptide, Serum

Laboratory assay overview

C-Peptide is useful in the evaluation of pancreatic beta cell function (e.g., helping distinguish type 1 from type 2 diabetes mellitus, or monitoring patients who have received islet cell or pancreatic transplants) and for determining the source of insulin in patients with hyperinsulinemic hypoglycemia (e.g., distinguishing insulin-secreting tumors from exogenous insulin administration). It is also sometimes measured as an additional means (more resistant to hemolysis than is insulin itself) for evaluating glucose tolerance tests.

Laboratory assay overview

The principal use of C-peptide is in the evaluation of hypoglycemia. Patients with insulin-secreting neoplasms have high levels of both C-peptide and endogenous insulin; in contrast, patients with factitious hypoglycemia will have low C-peptide levels in the presence of elevated (exogenous) serum insulin. C-peptide is also useful in evaluating residual beta-cell function in insulin-dependent diabetics, many of whom have antibodies that interfere with insulin assays. Glucagon-stimulated C-peptide concentration has been shown to be a good discriminator between insulin-requiring and non−insulin-requiring diabetic patients. The diagnosis of islet cell tumor is supported by elevation of C-peptide when plasma glucose is low.

Laboratory assay overview

This test is used for C-peptide measurement.

Laboratory assay overview

The determination of insulin in serum is primarily used for the diagnosis of glycemic disorders in diabetic and pre-diabetic patients in the assessment of insulin resistant syndromes. Insulin is synthesized by the pancreatic beta cell as a precursor, proinsulin. Proinsulin is processed to insulin and C-peptide, a contiguous peptide between the insulin A and B chains, as it passes through the cell. The C-peptide in the proinsulin ensures correct folding and processing of proinsulin as it passes through the cell. Both insulin and C-peptide are released together from the beta cells in response to increased glucose levels. Because of differences in half-life and hepatic clearance, peripheral blood levels of C-peptide and insulin are no longer equimolar but remain highly correlated. A steady-state plasma glucose test in individuals undergoing an insulin suppression test to assess insulin resistance found that the combination of insulin and C-peptide was a better indicator of insulin resistance than either one individually.

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.

Laboratory assay overview

This test reflects the patient's beta cell function. It, therefore, is a marker for endogenous insulin production with or without exogenous insulin injection. C-peptide is not affected by the presence or absence of insulin antibodies.

Laboratory assay overview

This panel is for early assessment of metabolic risk, using carefully selected tests that identify early metabolic deviations indicating disease risk. This panel has been selected to identify physiological changes oftentimes evident before the manifestation of common metabolic syndrome risk factors, to aid practitioners in identifying risk and delaying or preventing disease progression.